Inclusion Criteria:~* Prior to participation in this study, each prospective study individual must sign an
informed consent form.~* Diagnosis of probable or possible Alzheimer's disease according to NINDS-ADRDA and
DSM-IV criteria.~* Not actively participating in another clinical drug trial.~* MMSE range 12-28 at entry.~*
Hachinski Modified Ischemic score < or =4.~* Accompanied by appropriate caregiver who can aid in administration
of medication and make assessments.~* Good general health as evidenced by physical, neurological and clinical
laboratory examination.~* Education level > or = 9th grade or equivalent.~* Fluent in the English language.~*
Reliable caregiver.~* Able to complete neuropsychological tests.~* Ambulatory.~* On stable doses of medications
for the treatment of non-excluded medical conditions for four weeks prior to screening.~* Able to participate
in all scheduled evaluations.~* Geriatric Depression Scale < or = 20.~* Not exceeding 400 IU of Vitamin E for
30 days.~* For patients currently taking donepezil, they must remain on a stable dose for at least three
months. Individuals taking stable doses of other cholinesterase inhibitors can be included, but no study
subject may initiate use of any cholinesterase inhibitor after entrance to trial.~* Individuals of both sexes
over 50 years of age will be eligible.~
